Full Press Release Details
Results from B-YOND Extension Study Reinforce Long-Term Clinical Profile of ALPROLIX for the Treatment of Hemophilia B.
BIIB
Results from B-YOND Extension Study Reinforce Long-Term Clinical Profile of ALPROLIX for the Treatment of Hemophilia B
Key Takeaway: Results from B-YOND Extension Study Reinforce Long-Term Clinical Profile of ALPROLIX for the Treatment of Hemophilia B
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis